NVCT Nuvectis Pharma, Inc.
P/E
--
Forward P/E
--
Price/Sales
--
Beta
-0.242
Div Yield
--
Market Cap
--
Company Analysis
Latest News
Nuvectis Pharma's third quarter 2026 results feature a $140M cash balance and China drug approval
Nuvectis Pharma reported a third quarter 2026 net loss of $30.1 million, significantly widening from $7.5 million in the prior year due to $21.8 million in...
Nuvectis Pharma Inc Q3 2026 Earnings Preview: What Analysts Expect on November 03, 2026
Nuvectis Pharma is expected to report a Q3 2026 loss of $0.22 per share with zero revenue as a clinical-stage biotech, while the stock trades at $12.45 against...